​Spotlight: What if the biggest risk to pharma isn’t regulation, competition, or pricing—but oil?

Yes, today, pharma’s biggest risk is no longer in the lab—it’s in the energy market. The oil & gas crisis isn’t just driving up costs—it’s rewriting the rules of the pharmaceutical industry.

From API synthesis to biologics, from regulatory rigidity to financial volatility, pharma is facing a molecular-level supply shock. What looks like an energy issue is actually a system-wide disruption across chemistry, compliance, supply chains, and global access.

This blogpost highlights how 15 interconnected layers—from formulation risk to geopolitics—are converging to create a new operating reality.

The takeaway is clear: this is not a cost problem. It’s a system design problem.

Leaders who act now will redesign pharma for resilience. The rest will be left managing a model that no longer works.

If you’re in a pharma leader or a decisionmaker, the question is not if this oil crisis will impact your business—but how prepared you are to redesign for it. Now is the time to act.
​
To know more, checkout my blogpost below…

Beyond Energy:

The current oil and gas crisis is often framed through the lens of energy economics—fuel shortages, rising transportation costs, and inflationary pressure across industries. However, for the pharmaceutical sector, this crisis runs far deeper. It is not merely an energy disruption; it is a molecular supply shock that threatens the very building blocks of drug development, manufacturing, and global access.

Unlike many industries that can adjust inputs or suppliers with relative flexibility, pharmaceuticals operate within tightly regulated, highly specialized systems. As a result, the ripple effects of energy volatility are amplified—impacting not just cost structures, but formulations, regulatory pathways, and ultimately, patient access to medicines.

What is unfolding is a systemic, multi-dimensional shock that penetrates the industry at fifteen interconnected layers such as:
Molecular (inputs and materials), Regulatory (compliance and approval constraints), Operational (manufacturing and supply chains), Financial (cost volatility and capital exposure), Geopolitical (access, policy, and national security) and more...

And these layers are not independent—they reinforce one another. The result is a non-linear risk environment where disruptions amplify as they move through the system.

The core insight is— energy volatility is now directly coupled to the availability, design, and distribution of medicines.
Having said that, let us now take a quick look at how the oil & gas crisis is reshaping the pharmaceutical industry and what strategic shifts must be done to redefine the pharma operational model…

1. The Crisis as a Molecular Supply Shock
Molecular Dependency: The Hidden Backbone of Pharma

At a foundational level, modern pharmaceuticals are deeply embedded in petrochemical value chains.
Oil and gas derivatives underpin:

• API synthesis pathways (solvents, catalysts, intermediates)
• Drug formulation systems (excipients controlling solubility, stability, release kinetics)
• Packaging ecosystems (blister packs, vials, syringes, closures, labelling ink, adhesives)
• Bioprocessing infrastructure (single-use bags, tubing, filters)

This creates a material monoculture—a system optimized around petrochemical availability.

Failure Mode Under Stress
When upstream petrochemical supply tightens:

• Substitution options exist chemically, but not regulatorily
• Lead times for alternative sourcing expand dramatically
• Quality consistency becomes harder to maintain

Disruptions in oil and gas availability cascade upstream into chemical/ API manufacturing, creating shortages and price volatility in these essential inputs.

This reframes the crisis as a constraint on molecular availability, not just a procurement issue or an increase in operating costs.

The industry’s dependency is not just economic—it is embedded in the chemistry of its products.
 
2. From Cost Inflation to Formulation Risk
Conventional analysis tends to emphasize cost escalation. While valid, this view underestimates a more critical issue: formulation rigidity.

Pharmaceutical formulations are not flexible engineering systems—they are locked configurations validated through years of data.

Why Substitution Is Hard
Changing even a minor component can:

• Alter impurity profiles (impacting safety)
• Affect bioavailability (impacting efficacy)
• Change stability (impacting shelf life)

This triggers:

• full or partial revalidation
• regulatory filings and review cycles
• potential market delays

Strategic Implication
The industry faces a decoupling between technical feasibility and operational feasibility:

• Technically: substitution is often straightforward
• Practically: substitution is slow, expensive, and uncertain

This introduces a new category of systemic exposure— Formulation risk--where supply shocks propagate into regulatory and commercial delays.

In practical terms, a shortage of a single solvent or excipient can delay production for months—not because alternatives don’t exist, but because switching them is scientifically and regulatorily constrained.

Thus, the oil and gas crisis introduces a new category of risk— Formulation risk, where supply disruptions force technically feasible but regulatorily complex changes.
 
3. Regulatory Systems: Designed for Stability, Not Volatility
Regulatory frameworks were built to ensure consistency, safety, and traceability—not rapid adaptation.

The pharmaceutical industry’s greatest strength—its rigorous regulatory framework—is also a source of vulnerability in times of disruption.
​
Any change in:

• raw material supplier
• manufacturing site
• process conditions

requires filings with regulatory agencies such as Health Canada, USFDA, EMA or other country-specific regulators.

​These processes are:

• time-intensive
• documentation-heavy
• uncertain in outcome

As a result, supply chain disruptions triggered by energy crises cannot be resolved through rapid substitution. Instead, they create regulatory bottlenecks, where production delays are driven not by capability, but by compliance timelines.
 
4. Biologics: High-Value, High-Vulnerability
While small-molecule drugs are affected, the risks are even more pronounced in biologics and advanced therapies.

Spotlight: In Pharma and MedTech, business continuity is not about preventing disruption at all costs—it is about honoring responsibility when disruption inevitably occurs.

When patient access, product integrity, and system-wide trust are at stake, continuity stops being a checklist exercise and becomes a leadership mindset.

Quietly but decisively, business continuity in life sciences has shifted from an operational safeguard to a strategic differentiator. As supply chains globalize, risks become systemic, and healthcare expectations evolve, continuity is no longer just about recovery—it is about resilience, governance, and trust.

This reflection explores how Pharma and MedTech organizations are rethinking continuity beyond compliance, embedding it into culture, decision-making, and long-term strategy.

👉 Read the full piece below.
​
For advisory discussions on business continuity, operational resilience, or risk-informed decision frameworks in pharma and MedTech, feel free to connect or reach out directly.

Business Continuity in Pharma–MedTech: From Operational Safeguard to Strategic Imperative
Business continuity in the pharma and MedTech sectors is no longer a backstage operational function. It has evolved into a defining pillar of organizational credibility, resilience, and long-term value creation. In industries where patient safety, product integrity, and uninterrupted access to care are non-negotiable, continuity is not simply about keeping the lights on—it is about sustaining trust across an increasingly complex ecosystem.

Historically, continuity planning in life sciences was framed around compliance readiness and disaster recovery. While these foundations remain essential, recent global disruptions—from supply chain volatility to workforce dislocation and rapid shifts in healthcare delivery models—have expanded the conversation. Today, continuity is as much about adaptability as it is about preparedness.

Continuity Beyond Facilities and Systems
One of the most significant shifts has been the recognition that business continuity extends far beyond physical sites or IT infrastructure. In pharma and MedTech, resilience is deeply interconnected across research, manufacturing, quality, logistics, regulatory engagement, and post-market support.

Disruptions rarely remain isolated. A constraint in one function often triggers downstream consequences that are neither linear nor immediately visible. As a result, continuity thinking is becoming more holistic focusing on supplier dependencies, knowledge concentration, data flows, and decision-making latency. This broader lens does not replace established controls; it complements them by acknowledging that modern risk is increasingly systemic.

The Human Dimension of Resilience
People remain one of the most underestimated components of business continuity. Specialized expertise, tacit knowledge, and cross-functional coordination are core assets in the pharma–MedTech environment.

Sustaining operations during disruption requires more than documented procedures. It depends on empowered teams who understand priorities, escalation paths, and ethical boundaries. Organizations that treat continuity as a shared responsibility—rather than a compliance artifact—tend to demonstrate greater agility under pressure. Clear communication, role clarity, and visible leadership become stabilizing forces when normal operating assumptions are challenged.

Supply Chains as Strategic Assets
Life sciences supply chains have grown more global, specialized, and interdependent. Continuity planning increasingly reflects this reality by emphasizing visibility, optionality, and collaboration rather than simple redundancy.

The objective is not to eliminate risk—an unrealistic ambition—but to anticipate vulnerabilities and respond in a measured, principled manner. Importantly, continuity in this context extends beyond short-term response. It informs longer-term strategic decisions around sourcing models, capacity planning, and technology investments—each of which shapes an organization’s ability to serve patients consistently over time.

Governance, Not Guesswork
In regulated industries, business continuity must coexist with strong governance. Effective approaches are grounded in clearly articulated policies, defined ownership, and regular review—without drifting into rigidity.

The most resilient organizations balance discipline with discretion, ensuring that responses remain aligned with quality standards, ethical expectations, and organizational values even under pressure. This balance reinforces confidence among stakeholders without positioning continuity planning as a substitute for regulatory judgment or formal obligations.

A Living Capability, Not a Static Plan
Perhaps the most enduring lesson is that business continuity is not a one-time exercise or a document to be archived. In pharma and MedTech, it is a living capability—refined through learning, tested through experience, and strengthened through reflection.

Organizations that embed continuity into their culture move beyond crisis management toward sustained resilience. They view disruption not only as a risk to mitigate, but also as a signal to reassess assumptions, improve coordination, and reinforce their commitment to patients and healthcare systems.

Closing Reflection
In the end, business continuity in the pharma–MedTech sectors is less about contingency and more about intent. It reflects an organization’s readiness to uphold its purpose under imperfect conditions. When approached thoughtfully, continuity becomes a strategic enabler—quietly supporting innovation, safeguarding trust, and ensuring that critical therapies and technologies remain available when they are needed most.

If your organization is exploring how to strengthen resilience across quality, operations, or supply chains—without compromising governance—this is a conversation worth having.

I work with leadership teams to frame business continuity as a strategic capability aligned with organizational priorities and regulatory expectations.
​
Disclaimer
This article reflects observed industry trends and professional perspectives and does not constitute regulatory, legal, or operational advice. Read full disclaimer here.
 
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).

Keywords and Tags:
#BusinessContinuity #Pharma #MedTech #LifeSciences #OperationalResilience #SupplyChainResilience #QualityCulture #RiskManagement #HealthcareInnovation #Leadership
#Strategy #Governance
​
​​Categories:  Operational Excellence | Life Science Industry | Business Continuity

​Follow Shruti on YouTube, LinkedIn

​Spotlight: Is your patenting process slow, expensive, or inconsistent?
Operational excellence isn't just for manufacturing — it is critical for IP too.

Many organizations treat patenting as a legal formality rather than a strategic, process-driven function. But without structured workflows, clear ownership, and measurable KPIs, the result is often inefficiency, missed filings, and rising costs.

By applying principles like Lean, Kaizen, Hoshin, Six Sigma, or digital transformation to the patenting lifecycle — from invention disclosure to prosecution — companies can reduce bottlenecks, enhance collaboration, and improve time-to-grant.
​
Ask yourself:

• Do you track invention throughput with enough importance like you would do for a production line?
• Are you measuring the quality of filings and not just their quantity?
• Is your IP strategy integrated into your R&D framework?

If not, it’s time to rethink how you operate. Read the full post below to learn more …
​
If you're navigating patent process inefficiencies, let’s talk. I’ve worked with teams tackling similar challenges.

​In an innovation-driven economy, intellectual property (IP) is one of the most critical assets for a business. Yet, many organizations face inefficiencies in their patenting processes that can slow down innovation, increase costs, and reduce competitive advantage. Operational excellence in the patenting process is not just about filing patents faster—it’s about precision together with maximizing the value, quality, and impact of your intellectual property. 

Here’s how organizations can elevate the operational excellence of their patenting process:

1. Standardize Procedures
Standardization is the backbone of operational efficiency. Establish clear, repeatable protocols for drafting, filing, and tracking patent applications. This minimizes ambiguity and ensures consistency across teams and geographies. Use templates for patent disclosures and filing documentation to reduce variation and increase quality control.

Tips:

• Develop SOPs (Standard Operating Procedures) for each stage of the process.
• Create checklists to ensure critical steps are not overlooked.
• Train teams to follow uniform drafting and review formats.

2. Leverage Digital Tools and Automation
Digital transformation is essential in modern IP management. Invest in patent management systems that can handle documentation, automate alerts for deadlines, and streamline communication with patent offices.

Tools and Features to Consider:

• Document management systems and version control.
• Automated docketing and deadline reminders.
• Centralized dashboards for tracking application status and workloads.
• AI-based tools for prior art search and claim analysis.

3. Implement KPIs and Metrics
You can improve what you measure. Key Performance Indicators (KPIs) offer valuable insights into the efficiency, quality, and outcomes of the patenting process. Here are some KPIs you might want to use to evaluate your patenting processes-

• Average time from invention disclosure to filing.
• Patent grant rate using data from number of patents filed Vs. granted.
• Cost per filing.
• Patent maintenance and abandonment rates.
• Inventor satisfaction scores.

Regularly review these metrics to justify budgets, identify bottlenecks and areas for process improvement.

4. Foster Cross-Functional Collaboration
Patents do not live in a vacuum—they intersect R&D, legal, and business strategy. Operational excellence depends on these functions working in-sync. Some of the best collaboration practices are:

• Establish patent committees that include members from legal, R&D, and business development.
• Encourage early engagement between inventors and IP teams.
• Align patent filing decisions with strategic business goals and competitive landscapes.

This alignment ensures that patents support broader innovation objectives and generate maximum commercial value.

5. Continuously Review and Improve Processes
Operational excellence is a moving target. Regularly evaluate your patenting workflows to uncover inefficiencies and make incremental improvements. Some of the avenues to check are:

• Conduct post-mortems on failed or delayed filings.
• Solicit feedback from inventors and examiners.
• Benchmark against industry best practices and competitors.
• Monitor law changes, filing procedures and global trends

Continuous improvement not only reduces delays and errors but also ensures agility, compliance, and long-term ROI.

Final Thoughts
Achieving operational excellence in the patenting process isn’t a one-time project—it’s a sustained effort involving strategy, technology, and culture. By standardizing operations, leveraging digital tools, using data-driven insights, and promoting cross-functional alignment, organizations can transform their patenting processes from a compliance necessity into a strategic asset.

A streamlined, high-performing patent operation supports faster innovation, protects valuable inventions, and ultimately drives business growth in today’s competitive landscape.

Improving patent operations is a journey. Looking to optimize your IP strategy or processes? Let’s connect.

How is your organization streamlining its patenting process? Let’s share ideas—drop your thoughts in the comments.
​
I’ll be sharing more on IP strategy, innovation management, and legal ops in future posts—follow me on LinkedIn to stay updated.

More Operational Excellence Case Studies at: https://www.drshrutibhat.com/blog/category/case-studies

Keywords and Tags:
#Patents #OperationalExcellence #IPStrategy #InnovationManagement #LeanIP #DigitalTransformation #RAndD #InventionToImpact #ProcessImprovement #LegalOps #DrShrutiBhat
​​
Categories:  Operational Excellence | Patents | Process Improvement

​Follow Shruti on Twitter, YouTube, LinkedIn

Leading organizations through crisis is not what we want as leaders, but we must be prepared for it at all times, to maintain business continuity. One such crisis is power outage.

I am not getting into reasons why power outages happen, because that’s not the focus of this blogpost. As an Operational Excellence expert, I’m sharing insights every organization can act on before the lights go out.

Here’s a 6-point strategic guide to safeguard operations during power outages—from risk assessments and business continuity planning to technology adoption and emergency response.

Whether you're running a data center, R&D lab, retail operation or manufacturing site, understanding potential direct and indirect losses—from inventory spoilage to compliance violations—is key to designing a solid business continuity plan.

By the way, I've also included an Emergency Power Outage Response Template and a Business Continuity Checklist for R&D Facilities in this blogpost, so you can get started today.

Don’t wait for the next outage. Resilience starts with preparation. Checkout the full post below…

Ensuring business continuity and operational excellence during power outages involves a multifaceted approach. I am giving my perspective and insights as an Operational Excellent Expert, about how companies can embrace proactive measures which may help them maintain business continuity during such crisis.

Here's a six- point comprehensive guide to help your organization navigate and mitigate the impacts of such events:​

 1. Conduct a Comprehensive Risk Assessment

• Identify Critical Operations: Determine which business functions are essential and must remain operational during a power outage.
• Assess Vulnerabilities: Evaluate how a power failure could impact these critical areas, considering both financial and operational repercussions. ​

 
2. Develop a Robust Business Continuity Plan (BCP)

• Backup Power Solutions: Invest in reliable backup generators and uninterruptible power supplies (UPS) to maintain power to essential systems.
• Data Protection: Implement regular data backups and consider cloud-based solutions to ensure data integrity and accessibility.
• Communication Protocols: Establish clear communication channels and protocols to keep employees, stakeholders, and customers informed during outages.
• Supply Chain Coordination: Work closely with suppliers and partners to develop contingency plans that address potential disruptions in the supply chain. ​

To learn more about business continuity plan and how to set up one, checkout my video playlist: Business Continuity in a Crisis
 
3. Regular Testing and Training

• Emergency Drills: Conduct regular drills to test the effectiveness of your business continuity plan and ensure all employees are familiar with their roles during an outage.
• Plan Reviews: Periodically review and update your business continuity plan to incorporate lessons learned from drills and actual events, ensuring it remains current and effective. ​

4. Establish Alternate Work Sites

• Backup Sites: Consider setting up alternate work locations, such as hot, warm, or cold sites, to ensure business operations can continue if the primary site is compromised.
• Remote Work Capabilities: Enhance remote work infrastructure to allow employees to work from home or other locations during outages. ​

5. Implement Operational Excellence Strategies

• Continuous Improvement: Adopt methodologies like Lean, Kaizen and Six Sigma to streamline processes and eliminate inefficiencies.
• Performance Monitoring: Utilize key performance indicators (KPIs) to monitor operations and identify areas for improvement.
• Employee Engagement: Foster a culture of continuous improvement by involving employees in problem-solving and decision-making processes. ​

6. Leverage Technology and Automation

• Outage Management Systems (OMS): Deploy OMS to detect, manage, and restore power outages efficiently, integrating with other systems for real-time situational awareness.
• Distributed Energy Resources (DERs): Incorporate DERs like solar panels and battery storage to provide alternative power sources during outages. ​

By proactively implementing these strategies, businesses can enhance their resilience against power outages, ensuring continuity of operations and maintaining a competitive edge even during unforeseen disruptions.

Make sure to include a power outage emergency response plan within your business continuity plan. You may want to checkout the Power Outage Emergency Response Plan template here.

​An important point to research before designing your business continuity plan is to find out what are the various direct and indirect losses for your business. This is a vital aspect to consider because it hugely impacts your business’s revenues and profit.

Types of loss (for a business) due to power outages-
Power outages can lead to a wide range of direct and indirect losses for businesses, depending on the industry sector, product mix, duration of the outage, and preparedness level.

There are seven main avenues of losses due to power outages, namely-

1.Operational disruptions- These include halted manufacturing, lost production hours, productivity, missed deadline etc.

2.Inventory and product loss- These encompass spoilage, damage to perishable goods etc. Say for example- a cold storage facility that housed meat and sea food lost refrigeration for four hours due to a power outage. This will result in damaged goods i.e. inventory loss.

3.IT and data loss- like corruption of files, lost transactions, downtime etc.
For instance, a financial services firm can lose access to its cloud-based trading platform during peak hours due to power outage. This can result in clients reporting failed trades, loss of customer’s confidence as well as potential liability.

​4.Revenue loss- such as missed sales, online platform outages etc. For instance, an e-commerce company’s website that went offline (due to the power outage) during a national sale will result in missed online transactions, huge losses in sales and revenues.

5.Customer dissatisfaction and reputation damage- like trust erosion, contract breaches etc. For example, a call center failed to respond to customer queries due to power failure, had dissatisfied customers. Now, if this is a one-time incident, customers are usually forgiving. But if this is a frequent phenomenon, it can potentially bring negative press, social media backlash and perhaps long-term customer loss.

6.Safety and compliance violations- like breach of regulations, safety risks etc. For instance, a chemical processing plant had no backup lighting or cooling due to the power outage. This resulted in unsafe storage conditions leading to regulatory fines and legal risk.

7.Extra costs for recovery- includes emergency equipment rentals, overtime pay etc. For example- a logistics company had to rent diesel generators and pay night crews to fulfill backlog orders, which resulted in huge unplanned recovery costs.

​The duration a business should plan for continuity during power outages depends on the industry, location, critical operations, product types and risk appetite, but general best practices recommend planning for three tiers of outage durations:

📌 Industry Benchmarks (recommended, must be customized for your business):

• Data centers / hospitals: Plan for 72+ hours with backup generators, fuel reserves, and secondary data centers.
• Manufacturing: Often plan for 24–48 hours, focusing on process preservation and minimizing loss.
• Retail / e-commerce: Focus on 12–24 hours with online redundancy and off-site order processing.
• Cold chain / pharma: Require immediate backup and 72+ hours of temperature control continuity.

Practical Guidelines

• Critical operations: Plan for at least 72 hours of uninterrupted power via backup sources.
• Support functions (HR, admin, etc.): Can rely more on remote work and may not need immediate continuity.
• Recovery & return-to-service: Should be scoped out for 7 days minimum in high-risk areas.

As an example, I have given Power Outage Business Continuity Checklist tailored for R&D facilities, with a focus on protecting experiments, equipment and data integrity; you may want to checkout the document here.​

Power outages shouldn't halt your business! Equip your organization with a robust business continuity strategy today. Let’s elevate how we prepare for the unavoidable.

Share how your organization prepares for power outages—or if you’re starting now, feel free to reach out with questions. Want to dive deeper? Watch my full Business Continuity in a Crisis video playlist.
​
If you’re rethinking your organization’s approach to power resilience, I’d welcome the conversation.

Keywords and Tags:
#BusinessContinuity #OperationalExcellence #PowerOutage #RiskManagement #EmergencyPreparedness #ResilienceStrategy #BusinessStrategy #ContinuityPlanning #Leadership #DisasterRecovery #OperationalRisk
​
Categories:  Business Continuity | Operational Excellence | Checklists

Follow Shruti on Twitter, YouTube, LinkedIn

When the Power Fails, Science Shouldn’t.
​
Research and development environments are uniquely vulnerable during power outages. From temperature-sensitive reagents to delicate ongoing experiments, even a brief interruption can compromise months of work, threaten compliance, and jeopardize safety.

That’s why business continuity in R&D isn’t just about keeping the lights on—it’s about protecting knowledge in motion.

Here’s a targeted Power Outage Business Continuity Checklist specifically for research facilities. It’s a proactive framework built around six key pillars, namely:

1. Backup Power Systems – Ensuring UPS coverage for critical lab equipment and validated generator transitions.
2. Experiment & Lab Preservation – Protocols to safeguard priority experiments and sensitive materials.
3. Data Protection & IT – Redundant storage, emergency saves, and offline workarounds.
4. Personnel & Safety – Clear roles, trained staff, and accessible emergency supplies.
5. Documentation & Communication – SOPs, contact trees, and internal alert systems.
6. Supplies & Contingencies – From spare parts to emergency budgets, readiness at every level

​Continuity in R&D isn't just operational—it's strategic. In regulated, high-stakes environments, preparation is the only real safeguard for progress. Checkout the document below …
​

If your lab’s resilience depends on more than just backup power, it may be time to reassess your continuity planning.

​Let’s discuss how your facility can prepare, protect, and recover with confidence.

Keywords and Tags:
#RDContinuity #LabResilience #BusinessContinuityPlanning #PowerOutagePreparedness #ScientificOperations #EmergencyReadiness #PharmaOps #ResearchContinuity #CrisisManagement #FacilityPreparedness
​
Categories:  R&D Leadership | Operational Excellence | Checklists

Follow Shruti on Twitter, YouTube, LinkedIn

Power Outages Are Inevitable. Chaos Doesn’t Have to Be.

In today’s ‘always-on’ world, even a brief power outage can ripple across operations, jeopardize safety, and erode stakeholder trust. The real differentiator is not whether outages happen—but how we respond when they do.

A well-structured Power Outage Emergency Response Plan transforms disruption into managed risk. It provides clarity when uncertainty strikes, guiding teams through a coordinated, step-by-step response from the first flicker of darkness to full operational restoration.

This plan outlines six critical phases:

1. Immediate Response focused on personnel safety and initial stabilization
2. Initial Assessment to determine scope and activate continuity measures
3. Sustaining Operations to preserve business-critical functions
4. Communication Protocols to ensure transparency with all stakeholders
5. Recovery & Restoration to bring systems back online safely
6. Preparedness Measures that turn lessons learned into future resilience

What sets resilient organizations apart is not perfection, but preparation—tested systems, trained teams, and the ability to adapt under pressure.

If your business relies on continuous operations—or the trust of your employees, clients, and partners—power outage planning isn’t a checkbox. It’s a leadership imperative. 

Checkout the document below...

Let’s elevate how we prepare for the unavoidable.
​
If you’re rethinking your organization’s approach to power resilience, I’d welcome the conversation.

Keywords and Tags:
#BusinessContinuity #OperationalResilience #EmergencyManagement #LeadershipInCrisis #PowerOutagePlanning #RiskMitigation #ContinuityLeadership #CrisisPreparedness #FacilitiesLeadership #StrategicOperations
​
Categories:  R&D Leadership | Operational Excellence | Checklists

Follow Shruti on Twitter, YouTube, LinkedIn

​This checklist provides a robust foundation for developing a customized comprehensive crisis management plan for your chemical manufacturing company, ensuring preparedness and minimizing impact of the crisis. You may feel free to use this after doing due diligence and customization to suit your organization.

Keywords and Tags:
#CrisisManagement #ChemicalIndustry #BusinessContinuity #EmergencyPlanning #RiskManagement #DisasterRecovery #CrisisResponse #OperationalExcellence #SafetyProtocols #StakeholderEngagement #Compliance #BusinessResilience
​
Categories:  Business Continuity | Operational Excellence | Checklists

Follow Shruti on Twitter, YouTube, LinkedIn